Monopar Therapeutics Stock News

After losing some value lately, a hammer chart pattern has been formed for Monopar Therapeutics Inc. (MNPR), indicating that the stock has found support. This, combined with an upward trend in earning

After losing some value lately, a hammer chart pattern has been formed for Monopar Therapeutics Inc. (MNPR), indicating that the stock has found support. This, combined with an upward trend in earning

Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe and Enrolling Patients Toward Interim Analysis Anticipated in Q1 2023 Camsirubicin Phase 1b Dose­-Escalation Trial Now

Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe

WILMETTE, Ill., March 08, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to ext

WILMETTE, Ill., March 08, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to exten

WILMETTE, Ill., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to ext

WILMETTE, Ill., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to exte

WILMETTE, Ill., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ: MNPR ), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar''s Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference. The presentation will be available Full story available on Benzinga.com

WILMETTE, Ill., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend

Monopar Therapeutics Inc (MNPR) shares closed today 12.7% lower than it did at the end of yesterday. The stock is currently down 43.8% year-to-date, down 42.8% over the past 12 months, and down 87.0% over the past five years. Today, the Dow Jones Industrial Average rose 0.7%, and the S&P 500 rose 1.0%. Trading Activity Shares traded as high as $4.03 and as low as $3.42 this week.Shares closed 79.8% below its 52-week high and 0.6% above its 52-week low.Trading volume this week was 14.6% lower than the 10-day average and 42.4% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 49.8% The company's stock price performance over the past 12 months lags the peer average by 39.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Monopar Therapeutics Inc (MNPR) shares closed today at 0.6% above its 52 week low of $3.42, giving the company a market cap of $43M. The stock is currently down 43.8% year-to-date, down 42.8% over the past 12 months, and down 87.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 rose 0.3%. Trading Activity Trading volume this week was 42.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 49.8% The company's stock price performance over the past 12 months lags the peer average by 39.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Wall Street brokerages predict that Monopar Therapeutics Inc. (NASDAQ:MNPR) will report ($0.18) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Monopar Therapeutics earnings. The highest EPS estimate is ($0.16) and the lowest is ($0.20). Monopar Therapeutics reported earnings per share of ($0.19) during the same quarter last []

Brokerages expect Monopar Therapeutics Inc. (NASDAQ:MNPR) to announce ($0.18) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Monopar Therapeutics earnings, with estimates ranging from ($0.20) to ($0.16). Monopar Therapeutics posted earnings of ($0.19) per share in the same quarter last year, which indicates a []

WILMETTE, Ill., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the positive recommendation from its safety review committee to escalate to the second dose level in its camsirubicin Phase 1b trial in patients with advanced soft tissue sarcoma (ASTS). This decision was made following a review of safety data from the patients in the first dose cohort and will allow evaluation of a higher dose level of camsirubicin than has been administered in any prior clinical trial.